Avadel Pharmaceuticals Sets Date for Shareholder Meetings
Avadel Pharmaceuticals plc (NASDAQ: AVDL) has formally announced its intentions surrounding a significant transaction with Alkermes plc. The boards of both Avadel and Alkermes have reached a mutual agreement regarding the acquisition of Avadel's ordinary share capital. This Proposed Transaction marks a pivotal moment in Avadel's journey as a biopharmaceutical company, aiming to transform lives through innovative medicines.
Details of the Scheme Meeting and EGM
According to a recent announcement, the Irish High Court has ordered Avadel to convene a Scheme Meeting for shareholders. This essential gathering will provide an opportunity for shareholders to discuss and vote on the Scheme related to the Proposed Transaction. The Scheme Meeting is scheduled for January 12, 2026. It will commence at 10:00 a.m. local time, immediately followed by an Extraordinary General Meeting (EGM) at 10:15 a.m., which may adjust timing based on the conclusion of the Scheme Meeting.
Venue and Participation
Both the Scheme Meeting and the EGM will take place at the offices of Arthur Cox LLP in Dublin, creating a focused environment for shareholders to engage directly with company leadership. Shareholders will receive a detailed proxy statement, which serves as a comprehensive scheme circular outlining the terms of the Proposed Transaction, prior to the meeting date.
Understanding Avadel’s Vision
Avadel Pharmaceuticals is dedicated to developing innovative solutions that address the challenges patients face with current treatment options. Their flagship product, LUMRYZ™, is a once-at-bedtime oxybate formulation approved by the U.S. FDA, designed specifically for the treatment of cataplexy and excessive daytime sleepiness in patients suffering from narcolepsy. This demonstrates Avadel's commitment to improving patient care through cutting-edge science.
Engagement with Shareholders
As part of the lead-up to these critical meetings, the company emphasizes transparency. A full proxy statement will be mailed to shareholders, detailing not only the Proposed Transaction but also the rights and actions needed to support successful outcomes. Shareholder engagement and feedback are essential, and thus, Avadel strongly encourages participation in the Scheme Meeting.
Future Prospects and Commitment
Avadel is optimistic as it moves forward with its strategic plans involving this acquisition. The management team believes that alignment with Alkermes will enhance their capacity to innovate and expand into new therapeutic areas. Furthermore, Avadel is committed to ensuring that shareholders are well-informed and can make decisions based on thorough insights and documentation provided prior to the meetings.
Frequently Asked Questions
What is the purpose of the Scheme Meeting and EGM?
The Scheme Meeting and EGM are essential gatherings for Avadel shareholders to discuss and vote on the Proposed Transaction with Alkermes.
When will the Scheme Meeting take place?
The Scheme Meeting is scheduled for January 12, 2026, at 10:00 a.m. local time.
Where will the meetings be held?
Both meetings will be conducted at the offices of Arthur Cox LLP in Dublin.
What are the key highlights of the Proposed Transaction?
Alkermes aims to acquire the entire issued share capital of Avadel, positioning the combined entities for enhanced innovation and market reach.
What is LUMRYZ™, Avadel's flagship product?
LUMRYZ™ is a once-at-bedtime oxybate approved for treating narcolepsy, showcasing Avadel's commitment to transforming patient care with innovative treatments.
